Date Time
Significant reductions in COVID-19 infections found after single dose of Oxford-AstraZeneca and Pfizer-BioNTech vaccine
COVID-19 infections fell significantly – by 65% percent – after a first dose of the Oxford-AstraZeneca or Pfizer-BioNTech vaccines in this large community surveillance study.
Data from the COVID-19 Infection Survey, a partnership between the University of Oxford, the Office of National Statistics (ONS) and the Department for Health and Social Care (DHSC), is the first to show the impact of vaccination on antibody responses and new infections in a large group of adults from the general population aged 16 years and older.
Two studies, released today as pre-prints, focused on the protection from infection provided by COVID-19 vaccines. Researchers analysed 1,610,562 test results from nose and throat swabs taken from 373,402 study participants between 1 December 2020 and 3 April 2021. 21 days after a single dose of either Oxford-AstraZeneca or Pfizer-B
One dose of Pfizer or Oxford jab reduces Covid infection rate by 65% – study
msn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from msn.com Daily Mail and Mail on Sunday newspapers.
One dose of Pfizer or Oxford jab reduces Covid infection rate by 65% – study
msn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from msn.com Daily Mail and Mail on Sunday newspapers.
How the Covid-19 Genomics UK Consortium sequenced Sars-Cov-2
Consortium of universities and other institutions has harnessed datasets, analytics and cloud computing to sequence Sars-Cov-2, the virus that causes Covid-19, in a blisteringly short time
Share this item with your network: By Published: 12 Apr 2021
Genomics, the study of genes, is a field of biology that relies on computing. While the ability to sequence – effectively, read – the human genome has gained much attention, researchers have been quietly working to use the same techniques to track and analyse diseases. This work stepped into the limelight in 2020 by focusing on Sars-Cov-2, the virus that causes Covid-19.
E-Mail
Researchers at the Francis Crick Institute, as part of an international collaboration of scientists through the Pan-Cancer Analysis of Whole Genomes Consortium, have analysed the whole genomes of tumour samples from over 2,600 patients with different types of cancer. They identified a high prevalence of genetic diversity within individual tumours, which they further characterised. Their findings confirm that, even at late stages of development, tumour evolution is driven by changes that benefit the cancer.
When cancer cells divide, errors occur in the process of copying their DNA. These copying errors mean that different tumours can be made up of cells presenting a wide range of genetic diversity. This variation is a challenge for doctors as a treatment that works for one group of genetically related tumour cells, called a subclone, may not be effective against another. And certain subclones can initiate tumour spread or drug resistance.